← All trials
NCT05694364
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 25, 2023
- Primary completion
- Jan 31, 2026
- Completion date
- Jan 31, 2026
- First posted
- Jan 23, 2023
- Last posted
- Dec 6, 2023
- Enrollment
- 88
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of South FloridaLead sponsor
- IntrexonCollaborator
- University of South FloridaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.